VACCINE COMPOSITION AND IMMUNIZATION METHOD

摘要

The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.

主权项

1. A recombinant vaccine against leishmaniasis comprising a recombinant A2 protein of amastigote forms of Leishmania that allows serologic distinction between vaccinated and infected animals by conventional serologic tests, ELISA and immunofluorescence using antigens of promastigote forms selected from the group consisting of Leishmania amazonensis, L. donovani, L. infantum, and L. chagasi; wherein the recombinant vaccine contains: (i) recombinant A2-HIS (rA2) protein from 50 μg/mL to 200 μg/mL and adjuvant in a buffered saline solution, wherein the adjuvant is comprised of monophosphoryl lipid A or aluminum hydroxide plus CpG; and (ii) 0.01 mL of thimerosal per 1.00 mL of the buffered saline solution.